Evotec to Receive German Grant for H3 Receptor Antagonist Programme

28 April 2010 (Last Updated April 28th, 2010 18:30)

Evotec AG will receive €1.5m from the German Federal Ministry of Education and Research as a research grant to advance its H3 receptor antagonist programme. Evotec has identified and optimised H3 receptor antagonists for preclinical development and the grant will enable it to initiate Pha

Evotec AG will receive €1.5m from the German Federal Ministry of Education and Research as a research grant to advance its H3 receptor antagonist programme.

Evotec has identified and optimised H3 receptor antagonists for preclinical development and the grant will enable it to initiate Phase I clinical studies.

The histamine H3 receptor is a drug target as blocking it in brain can improve alertness and cognition.

H3 receptor antagonists are expected to become a new class of therapy in CNS indications and excessive fatigue associated with multiple sclerosis.